8 analysts have expressed a variety of opinions on Tempus AI TEM over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

On June 30, 2025, Guggenheim analyst Subbu Nambi reaffirmed a “Buy” rating on Tempus AI, Inc. (NASDAQ:TEM), while raising the firm’s price target from $65.00 to $75.00. The revised target ...

Tempus AI dropped for a second day on Monday, shedding 4.48 percent to close at $63.54 apiece following the announcement of a $400-million debt issuance.

Tempus AI is revolutionizing AI healthcare through genomics innovation and strong financial growth. Click here to read an analysis of TEM stock now.

The update means Personalis and Tempus will now work to bring to market the NeXT Personal ® ultra-sensitive, tumor-informed minimal residual disease (MRD) test to detect cancer recurrence in four ...

The collaboration aims to leverage Personalis’ MRD testing platform with Tempus’ market reach to more than 50% of U.S. oncologists, potentially allowing for earlier detection of cancer ...

Tempus AI, Inc. (TEM) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit Provided by PR Newswire Jul 9, 2025, 9:00:00 AM ...

Chicago-based Tempus AI, Inc. TEM is experiencing robust revenue growth, marked by record-setting financial performance. In the first quarter of 2025, the company reported a 75.4% year-over-year ...

NEW ORLEANS, July 09, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 12, 2025 to file lead plaintiff applications in a ...

Needing a reliable car shipping company for your vehicle? Learn about Tempus Logix, including shipping options and availability, and read reviews.

Get today's Tempus AI stock news. We cover the latest Tempus AI headlines and breaking news impacting Tempus AI stock performance.

Tempus AI, Inc is a healthcare technology company. The company is headquartered in Chicago, Illinois.